Journal Article Summary
The article investigates the potential predictors of atrial fibrillation (AF) in patients with acute coronary syndrome (ACS) who are treated with either ticagrelor or clopidogrel, two common antiplatelet medications. This topic is significant because AF is a common complication in ACS patients, which can lead to increased morbidity and mortality. Ticagrelor is known to elevate plasma levels of adenosine, a substance that may contribute to the development of AF, making it crucial to understand whether this medication poses a higher risk compared to clopidogrel.
In this study, researchers analyzed data from 831 ACS patients, dividing them into two groups based on their treatment: 410 received ticagrelor and 421 received clopidogrel. They measured various electrocardiographic and echocardiographic parameters, including P wave dispersion (PWD) and atrial electromechanical delay (EMD), to assess the risk of AF. The results showed no significant differences in these parameters between the two groups, indicating that ticagrelor does not increase the risk of AF compared to clopidogrel in this patient population.
However, the study has limitations, such as the lack of long-term follow-up to monitor for future AF episodes and potential confounding factors that could influence the results. Patients and caregivers should discuss these findings with healthcare professionals, especially if they have concerns about AF or are considering treatment options for ACS. Understanding the implications of these medications and their effects on heart health is essential for making informed decisions about treatment.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- ALGÜL Engin, SUNMAN Hamza, DURAL Muhammet, GULİYEV İlkin, AKER Mert, FELEKOĞLU Mehmet Ali, ERAT Mehmet, TULMAÇ Murat, et al.. Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel. Turkish Journal of Medical Sciences 2019. DOI: 10.3906/sag-1903-188. PMID: 31549494. PMCID: PMC7018378.
Featured Pill Pals Product
Clopidogrel 75 mg Tablets --- Generic For Plavix --- ScieGen
Clopidogrel 75 mg Tablets — Generic For Plavix — ScieGen is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
